Four of these five market-driving drugs—secukinumab (Cosentyx, Novartis), apremilast (Otezla, Celgene), crisborole (Eucrisa, Pfizer), and ixekizumab (Taltz, Eli Lilly)—were approved to treat psoriasis, and one, dupilumab (Dupixent, Celgene/Sanofi Genzyme), became the first and, to-date, the only biologic approved for ...